Sienna Biopharmaceuticals (SNNA) Given a $45.00 Price Target at Cowen

Cowen set a $45.00 target price on Sienna Biopharmaceuticals (NASDAQ:SNNA) in a research note issued to investors on Monday morning. The brokerage currently has a buy rating on the stock.

NASDAQ:SNNA opened at $6.31 on Monday. The stock has a market cap of $213.73 million, a PE ratio of -1.22 and a beta of 1.56. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.67. Sienna Biopharmaceuticals has a 1-year low of $5.53 and a 1-year high of $25.71.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by ($0.03). As a group, sell-side analysts anticipate that Sienna Biopharmaceuticals will post -2.95 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its holdings in shares of Sienna Biopharmaceuticals by 12,865.9% during the first quarter. Royal Bank of Canada now owns 5,705 shares of the company’s stock worth $107,000 after purchasing an additional 5,661 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Sienna Biopharmaceuticals during the third quarter worth about $182,000. Neuburgh Advisers LLC grew its holdings in shares of Sienna Biopharmaceuticals by 75.6% during the second quarter. Neuburgh Advisers LLC now owns 12,896 shares of the company’s stock worth $196,000 after purchasing an additional 5,552 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Sienna Biopharmaceuticals during the third quarter worth about $200,000. Finally, Bridgeway Capital Management Inc. bought a new stake in shares of Sienna Biopharmaceuticals during the third quarter worth about $225,000. Institutional investors own 48.18% of the company’s stock.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Featured Story: Understanding each part of a balance sheet

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit